Hospital-acquired pneumonia (HAP) is defined as pneumonia occurring ≥48 hours after admission and excluding any infection that is incubating at the time of admission.
Ventilator-associated pneumonia (VAP) is described as pneumonia occurring >48-72 hours after endotracheal intubation and within 48 hours after removal of endotracheal tube.
Early-onset HAP or VAP is the pneumonia occurring within the first 4 days of hospitalization that may be cause by antibiotic-sensitive bacteria that usually carries a better diagnosis.
Late-onset HAP or VAP is the pneumonia occurring after ≥5 days. It is likely caused by multidrug-resistant pathogens associated with increased mortality and morbidity.

Principles of Therapy

  • Antibiotic therapy should be started w/in 4 hours after diagnosis of hospital-acquired pneumonia (HAP) has been established
  • Prompt initiation of appropriate initial antibiotic therapy can decrease mortality
  • Empiric choice of antibiotic agents should take into consideration the local microbiology, availability, cost & formulary restrictions
    • Initial empiric therapy should be adapted to local patterns of antibiotic resistance & when possible each ICU should collect this information on a regular basis
  • Empiric therapy also needs to take into consideration what therapies the patient has received w/in the last 2 weeks
    • If patient has received antibiotics recently for a different infection, therapy should utilize an agent from a different antibiotic class for resistance is predicted by recent antibiotic exposure
  • An antibiotic course of 5-10 days is recommended for patients w/ confirmed HAP
  • Not only should appropriate antibiotics be used, they should be used at the optimum doses & correct route of administration
  • A major risk factor for mortality & increasing length of hospital stay is the administration of inappropriate antibiotics
  • All patients w/ HAP & ventilator-associated pneumonia (VAP) should be treated initially w/ intravenous (IV) therapy, but switch to oral therapy may be considered in some patients who are responding to therapy
  • Initial treatment of healthcare-associated pneumonia (HCAP) should be similar to that of HAP & VAP since spectrum of pathogens closely resemble late-onset HAP & VAP


Possible Pathogens
  • Streptococcus pneumoniae
    • Local resistance patterns should be followed because the frequency of Penicillin-resistant & multidrug- resistant S pneumoniae is increasing
    • An aminopenicillin at appropriate dose remains the treatment of choice for most Penicillin-resistant S pneumoniae w/ MIC ≤2 mcg/mL
  • Other potential pathogens
    • Haemophilus influenzae, Methicillin-sensitive Staphylococcus aureus (MSSA)
    • Gram-negative bacilli (eg Escherichia coli, Klebsiella pneumoniae, Enterobacter sp, Proteus sp, Serratia marcescens)
Early-onset hospital-acquired pneumonia (HAP)
  • Patients w/ early-onset HAP w/o risk factors for MDR organisms will likely respond to monotherapy w/ 1 of the following agents:
    • Beta-lactam/beta-lactamase inhibitor combinations (eg Amoxicillin/clavulanic acid or Ampicillin/sulbactam)
    • Nonpseudomonal 3rd generation cephalosporins (eg Ceftriaxone, Cefotaxime, Cefepime or Cefpirome)
    • Carbapenems w/o antipseudomonal activity (eg Ertapenem)
    • Quinolones (eg Levofloxacin or Moxifloxacin)
  • Patients who have allergy to beta-lactam agents may be given quinolone alone or monobactam plus Clindamycin
  • If combination therapy is indicated, quinolone or 3rd generation cephalosporins plus macrolide may be given
Early-onset ventilator-associated pneumonia (VAP)
  • The following agents are recommended in patients w/ early-onset VAP w/o risk factors for MDR organisms:
    • Antipseudomonal 4th generation cephalosporins
      • Cefepime & Cefpirome are more resistant to some beta-lactamases
    • Carbapenems w/ antipseudomonal activity (eg Imipenem or Meropenem)
    • Antipseudomonal beta-lactam/beta-lactamase inhibitors (eg Piperacillin/tazobactam)
  • If combination therapy is indicated, the following are recommended: Quinolones or aminoglycosides w/ or w/o glycopeptides (eg Vancomycin or Teicoplanin) or Linezolid
    • Some authorities recommend beta-lactam agent & aminoglycoside combination regimen based on improved survival rate
  • If L pneumophila is suspected, a quinolone should be included rather than an aminoglycoside
  • Those at risk for the above organisms should initially receive a combination of broad-spectrum coverage
    • This will decrease the risk of inappropriate antibiotic therapy
  • Concurrent treatment w/ 2-3 drugs should be considered in patients w/ late-onset VAP
Possible Pathogens
  • All the pathogens listed in treatment box B are possible causative organisms
Multidrug-resistant (MDR) pathogens
  • Pseudomonas aeruginosa, K pneumoniae, Acinetobacter sp, & Stenotrophomonas maltophilia
  • Extended-spectrum beta-lactamase-producing (ESBL) Enterobacteriaceae
  • MRSA should be considered if MRSA risk factors (eg antibiotic therapy prior to onset of pneumonia, prolonged hospital stay) are present, presence of severe pneumonia/sepsis &/or if there is high local incidence
  • Legionella pneumophila
Late-onset hospital-acquired pneumonia (HAP) & ventilator-associated peumonia (VAP)
  • The following agents are given in patients w/ late-onset HAP & VAP w/ risk factors for MDR organisms:
    • Antipseudomonal carbapenems (eg Imipenem or Meropenem)
    • Antipseudomonal beta-lactam/beta-lactamase inhibitors (eg Piperacillin/tazobactam)
    • Antipseudomonal cephalosporins: 3rd & 4th generation (eg Cefepime, Ceftazidime)
      • Recommended only in patients w/ late-onset HAP
  • If combination therapy is indicated, the following drugs are given: Antipseudomonal quinolones (eg Ciprofloxacin or Levofloxacin) or aminoglycosides (eg Amikacin, Gentamicin or Tobramycin)
    • Glycopeptides or Linezolid may be added in the regimen or as a 2nd drug if patient requires coverage for possible Methicillin-resistant S aureus (MRSA) pneumonia
Specific Pathogens

Suspected Pseudomonal Infection

  • Empiric treatment should include an antipseudomonal beta-lactam or carbapenem plus a quinolone or an aminoglycoside
  • Polymyxins B or E may be given as alternative drug if patient remains unresponsive
  • Choice of specific agents if Pseudomonas sp is found should be based on the results of sensitivity testing
  • Pseudomonas sp can rapidly develop resistance to all classes of antibiotics & resistance develops in 30-50% of patients who receive monotherapy
    • Evidence is lacking to show that this does not occur when combination therapy is used but there is limited data showing patients w/ Pseudomonas sp bacteremia are less likely to die when combination therapy is used
Acinetobacter sp
  • Acinetobacter sp have native resistance to many classes of antibiotics
  • Carbapenems, Sulbactam (eg Ampicillin/sulbactam or Cefoperazone/sulbactam) & Polymyxins B or E (eg Colistin) tend to be the most consistently effective agents
    • Carbapenem-resistant clones can be a problem & therefore, optimal dosing should be used
    • One study has documented the safety & efficacy of Colistin in patients w/ VAP that was resistant to carbapenem
  • Combination therapy of Imipenem plus Ampicillin/sulbactam or Sulbactam alone is recommended
  • Acinetobacter sp; however, Netilmicin has been shown to be effective in 50% of strains based on an Asian study
Extended-spectrum beta-lactamases (ESBL) Enterobacteriaceae
  • Carbapanems are generally a reliable choice
  • Tigecycline is effective against ESBL strains of K pneumoniae & E coli
  • Piperacillin/tazobactam has been proven to be highly active in vitro against K pneumoniae & E coli
  • Cephalosporin susceptibility is variable, therefore 3rd & 4th generation cephalosporins should not be used as monotherapy if this organism is suspected
    •  If Enterobacter sp is suspected, 3rd generation cephalosporins should be avoided because of possible emergence of resistance during treatment
  • If L pneumophila is suspected, antibiotic regimen should include a macrolide (eg Azithromycin) or quinolone (eg Ciprofloxacin or Levofloxacin) rather than an aminoglycoside
Methicillin-resistant Staphylococcus aureus (MRSA)
  • Vancomycin or Teicoplanin is recommended as1st-line agent for MRSA
  • Linezolid has been shown to have comparable or superior efficacy to Vancomycin in patients w/ HAP
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
05 Oct 2018
Majority of users of electronic nicotine delivery systems (ENDS) also use other tobacco products, a recent study has shown.
05 Nov 2015
Bronchiectasis incidence and prevalence is increasing in the UK according to a population-based cohort study from 2004 to 2013.
30 Jul 2018
Smoking marijuana may lead to cough, sputum production and wheezing, suggests a recent study with low-strength evidence. In addition, there is insufficient evidence supporting the association between marijuana use and obstructive lung disease.